Zymeworks closes acquisition of Theravance Biopharma
The Nasdaq-listed biotech finalized the merger on September 23, 2026, paying Theravance shareholders $17.00 in cash plus contingent value rights tied to ampreloxetine.
SEC filing
Latest
7 stories
Wednesday, September 23
Zymeworks-Theravance merger CVR agreement details milestone and royalty terms
A contingent value rights agreement filed by Theravance Biopharma sets payment terms tied to licensing, sales, and a first commercial sale milestone for ampreloxetine, dated September 22, 2026.
SEC filing
Wednesday, September 16
Gossamer Bio adds Greg Ciongoli to board and audit committee
The seralutinib developer named the Adiumentum Capital founder as a Class III director effective September 16, 2026.
SEC filing
Tuesday, August 25
FDA approves Ziihera in two regimens for first-line HER2+ gastroesophageal cancer
The approval triggers a $250 million milestone payment to Zymeworks from partner Jazz Pharmaceuticals, with more payments and royalties possible.
SEC filing
REGENXBIO adds Greg Ciongoli to board, two directors depart
The gene therapy company named an investment executive to its board while two longtime independent directors retired, effective August 25, 2026.
SEC filing
Monday, August 10
Theravance Biopharma reports Q2 2026 results, confirms Zymeworks deal on track for second half close
Theravance Biopharma said its previously announced acquisition by Zymeworks is expected to close in the second half of 2026, as YUPELRI revenue and cost cuts advanced.
SEC filing
Thursday, August 6
Zymeworks flags August 25 PDUFA date for zanidatamab, updates pipeline and Theravance timeline
Zymeworks said the FDA's target action date on zanidatamab in gastric cancer falls on August 25, 2026, while the Theravance Biopharma acquisition is still expected to close in the second half of the year.
SEC filing